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INTRODUCTION
In 1995, FDA issued a guidance Immediate Release Solid 
Oral Dosage Forms; Scale-up and Post approval Changes: 
Chemistry, Manufacturing, and Controls; in vitro Dissolution 
Testing; in vivo Bioequivalence Documentation (SUPAC-IR). 
The SUPAC-IR provides recommendations to sponsors 
of new drug applications (NDA’s), abbreviated new 
drug applications (ANDA’s), and abbreviated antibiotic 
applications (AADA’s) who intend, during the post-approval 
period, to change (i) the components or compositions; 
(ii) the site of manufacture; (iii) the scale-up/scale-down of 
manufacture; and/or (iv) the manufacturing (process and 
equipment) of an immediate release oral formulation. For 
each type of change, the SUPAC-IR also defines (i) levels of 
changes; (ii) recommended chemistry, manufacturing, and 
controls tests for each level of change; (iii) in vitro dissolution 
and/or in vivo bioequivalence tests for each level of change; 
and (iv) documentation that should support the change.[1-3]
If dissolution profile similarity is demonstrated for the 
formulations before and after the changes, then expensive 
in vivo bioequivalence testing can be waived. Various 
procedures have been proposed for statistical assessment 
of dissolution profile similarity. These methods include 
application of either a nested model or an autoregressive time 
series model to the correlations between cumulative percents 
dissolved at different time points, and consideration of 
Mahalanobis distance as a criterion for the assessment of 
similarity in dissolution profiles between two formulations. 
Comparison of profiles representing a cumulative event 
over time is not unique to the pharmaceutical sciences. For 
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equivalence dissolution profile, especially to assure similarity 
in product performance, regulatory interest is in knowing how 
similar the two curves are, and to have a measure that is more 
sensitive to large differences at any particular time point.[4-11]
Aceclofenac is a poorly water-soluble NSAIDS drug according 
to the BCS system (class II) and its dissolution is rate-limiting 
step for its absorption.[12-14] Drug absorption from solid dosage 
forms after oral administration depends on the release of the 
drug substance from the drug product, the dissolution or 
solubilization of the drug under physiological conditions, and 
the permeability across the gastrointestinal tract. Because of the 
critical nature of the first two of these steps, in vitro dissolution 
may be relevant to the prediction of in vivo performance.
In order to evaluate equivalence in dissolution profile 
among branded and generic formulations of poorly soluble 
drug, aceclofenac, observations were taken on a given 
experimental unit over time and Mathematical equations 
were applied to analyze discrimination in profile and to 
demonstrate curve shape and level of the profile.
EXPERIMENTAL DETAILS
Materials
Aceclofenac (ACE) was gifted from Mepro Pharmaceutical 
Pvt. Ltd. potassium dihydrogen orthophosphate (Qualigen, 
Mumbai), sodium bicarbonate (Qualigens, Mumbai) NaOH 
(Merck) and distill water were used throughout the study. 
Branded and generic formulations of 100 mg aceclofenac 
were purchased form a commercial market.
Methods
In vitro dissolution study
Dissolution was performed on five formulations of 
100 mg aceclofenac tablets, one branded (Reference) 
coded S1 formulation and four generic T1, T2, T3, T4 
formulations. Dissolution was carried out on six units 
of each formulation using USP apparatus-II (Paddle) at 
37 6 0.58C in 900 ml phosphate buffer medium of pH 
6.8 at 50 rpm. After appropriate time interval, a sufficient 
volume of sample was withdrawn and filtered through 
Whatman filter No. 41. Immediately, same volume of the 
fresh dissolution medium was transferred to the dissolution 
flask. Samples were collected at suitable time interval and 
analyzed spectrophotometrically at 275 nm.
Statistical evaluation
ANOVA-based procedures
One-way ANOVA plus post hoc Tukey testing of percentage- 
dissolved data were applied using Microsoft excel 2007.
Model-independent methods
Ratio test procedures
Three types of ratio test procedures were performed: 
Ratio test of percentage dissolved, ratio test of area under 
the curve, and ratio test of mean dissolution time. Each 
of these procedures compares the dissolution profile of 
two formulations at a particular time point. Descriptive 
statistic form data analysis tool on three types ratio test were 
performed to analyze standard error and a 90% confidence 
level for the mean value of ratio of percentage dissolved, 
AUC, and mean dissolution time.
Pairwise procedures
These include difference factor f1 and similarity factor f2 
(equations 1 and 2) and two indices of rescigno. Rescigno 
proposed a bioequivalence index (equation 3) to measure 
the dissimilarity between a reference and a test product-
based on plasma concentration as a function of time. This 
index can also be used for drug dissolution data. Like the 
ratio test procedure, pairwise procedures compare the 
dissolution profile of a pair of products and employ a 
90% confidence approach. The main advantage of the f1 
and f2 equations is to provide a simple way to describe the 
comparison of the data. The f1 factor measures the percent 
error between two curves over all the points.
f1 5  | |/
i n
in
i
p
R T R
= = ∑ ∑ −


















×
1
100   (1)
f2 5 1/ 50 1 1 100
2
1
log ( / ) ( ) + −










×
= ∑ p R T
i
p
  (2)
In both equations, R and T represent the dissolution 
measurements at P time points of the reference and test, 
respectively:
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where dR(t) is the reference product dissolved amount 
and dT(t) is the test product dissolved amount at each 
sample time point. i is any positive integer number. This, a 
dimensional, index always presents values between 0 are 1 
inclusive, and measures the differences between two 
dissolution profiles. This index is 0 when the two release 
profiles are identical and 1 when the drug from either the 
test or the reference formulation is not released at all.
Model-dependent methods
Model-dependent approaches including zero order, first order, 
Hixson-Crowell, Higuchi, and Weibull models as described J Young Pharm Vol 2 / No 1  23
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in Table 1 were applied considering amount of drug release 
from 0 to 90 min. The following plots were made: Cumulative 
% drug release vs. time (zero order kinetic model); log 
cumulative of % drug remaining vs. time (first order kinetic 
model); cumulative % drug release vs. square root of time 
(Higuchi model), cube root of drug % remaining in matrix 
vs. time (Hixson Crowell cube root law) and logarithm of the 
dissolved amount of drug vs. the logarithm of time (Weibull 
model).  [15,16] From the mean ratio of the model parameter and 
the SE of the mean ratio, a 90% confidence level was assessed.
RESULTS AND DISCUSSION
The FDA suggests some acceptable approaches for 
establishing similarity of dissolution profiles, such as the 
model-independent and model-dependent approaches, 
although any approach would be considered once it had 
been justified. As a result of the emphasis placed on the 
comparison of dissolution profile data in FDA guidance, 
interest among pharmaceutical scientists has focused on 
methodology used to compare dissolution profile. 
Table 2 depicted that the results of application of one-way 
ANOVA in drug release of aceclofenac-marketed formulations. 
It was concluded that the differences in the mean values 
among the treatment groups are greater than would be 
expected by chance, calculated F-value (3.325) is greater than 
tabulated F-value (3.055); and there is a statistically significant 
difference (P 5 0.038). To evaluate the difference among the 
four batches, the Tukey test was performed on the results of 
ANOVA. The results of the Tukey test showed that there was 
statistically significant difference amongst batch T3 and T4. 
ANOVA methods takes the variability in the dissolution profile 
data into account in the comparison at each time point, it 
ignores the correlation between the dissolution time points.[17] 
Visual graphical interpretations of profiles of the percentage 
of drug dissolved for formulation S1 and T1-T4 over a 90 min 
time period in Figure 1 clearly predict similarity in T1 with 
S1 as compared to T2-T4 formulations. Figures 2-4 represent 
the ratio of percent dissolved, the ratio of area under the 
curve of drug dissolved, and ratio of mean dissolution time 
for test with standard formulation, respectively. Formulations 
T2 and T4 dissolving greater than half amount of drug 
(0.75-0.79) to that of reference formulation within 15 min 
and more than 85% drug were found to be released within 
60 min in both the formulations. T3 formulation dissolving 
less than half amount of drug (0.50-0.59) to that of reference 
formulation till 60 min and more than 80% drug was found 
to be dissolved within 90 min. Figure 3 denoted that the ratio 
of area under the curve for T1 was always within 90% to S1. 
Over the 60 min, T2 and T4 formulations gave the value of 
0.7 and still was not 100% dissolved. For T3, ratio started with 
0.4 and reaches the value of 0.7 by 90 min. Table 3 illustrates 
that throughout the dissolution, the mean ratio of percentage 
drug dissolved, area under the curve, mean dissolution time 
for T1 to S1 formulation are always nearer to one and within 
90% of that from reference formulation. The ratio of mean 
dissolution time for T1 was always near to one, while for 
T2 and T4 it was found to be in a range of 1.2-1.4 times 
and for T3 it was about 1.8-2.4 times as long as to dissolve 
as compared to S1. The 90% confidence level for the mean 
ratio of percentage, AUC, and mean dissolution time were 
also found to be about twice the standard error (SE).
The f1 and f2 equations have been adopted by the FDA in 
various guidance documents. For the use of mean data, the 
coefficient of variation at earlier time points should not be 
more than 20% and not exceed 10% at later time points.[2]
Table 4 depicted the comparison of similarity, dissimilarity 
index as well as lower and upper rescigno indices. According 
Table 1: Mathematical models used to describe 
dissolution curves
Zero order Q1 5 Q0 1 K0t
First order ln Q1 5 ln Q0 1 Kt
Hixson-crowell Q0
1/3 – Q1
1/3 5 Kst
Higuchi Q1 5 KH
1/2
Weibull Log[2ln(12(m))] 5 blogt2loga
Table 2: Results of one-way ANOVA
ANOVA
Source of variation SS df MS F P - value F crit
Between groups 6072.356 4 1518.089 3.325194 0.038708 3.055568
Within groups 6848.123 15 456.5415
Total 12920.48 19
SS - Sum of squares; MS - Mean square error; df - Degree of freedom
Table 3: Descriptive statistic for the ratio test procedure
Ratio T1/S1 T2/S1 T3/S1 T4/S1
Percentage
Mean 1.0124 0.7919 0.5521 0.7568
Std. error 0.0367 0.0188 0.0399 0.0303
90% CL 0.0863 0.0442 0.0804 0.0611
Area under the curve
Mean 1.0243 0.7903 0.5534 0.7423
Std. error 0.0301 0.0158 0.0444 0.0239
90% CL 0.0708 0.0373 0.0896 0.0481
Mean dissolution time
Mean 0.9973 1.2587 1.8589 1.3908
Std.error 0.0409 0.0336 0.1339 0.025
90% CL 0.0963 0.0791 0.2698 0.0503
Table 4: Mean values of f1, f2 and two indices of rescigno
T1 vs S1 T2 vs S1 T3 vs S1 T4 vs S1
f1 5.60483 20.49834 48.56718 30.01353
f2 59.48955 34.95411 16.65016 26.47835
1 0.028063 0.031224 0.037012 0.032972
2 0.16752 0.176704 0.192385 0.18158324   J Young Pharm Vol 2 / No 1
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to the FDA guidance,[12] values of f1 between zero and 15 and 
of f2 between 50 and 100 ensure sameness or equivalence 
of the two dissolution profiles. Dissolution profile, from 
point of similarity and dissimilarity criterion, of T1 was 
best fitted to the S1 formulation. All other formulations 
were not fitted to the criteria of similarity and dissimilarity. 
This approach was simple to apply but disadvantage is that 
both equations do not take into account the variability or 
correlation structure of the data, are sensitive to the number 
of points used, and, from a statistical point of view, this 
method seems to be less discriminating than other methods. 
The literature revealed several issues relevant to the invariant 
property of f2 with respect to the location change, shape of 
the curve, and the unequal spacing between the sampling 
time points. The similarity factor is a sample statistic that 
cannot be used to formulate a statistical hypothesis for 
the assessment of dissolution similarity. Therefore, it is 
impossible to evaluate false positive and false negative rates 
of decisions for the approval of drug products based on 
f2. Rescigno proposed a bioequivalence index to measure 
the dissimilarity between a reference and a test product 
based on plasma drug concentration time profile. This can 
also be used on dissolution concentrations. In the present 
evaluation, lower indices of rescigno were roughly same 
for all formulation but upper indices values 2 were larger. 
The indices are more difficult to compute than the f1 or f2 
equation.[7]
Quantitative interpretation of the values obtained is 
easier using mathematical equations that describe the 
release profile in function of some parameters related 
with the pharmaceutical formulations. The drug transport 
inside the pharmaceutical system and its release sometimes 
involve multiple steps provoked by different physical 
or chemical phenomena, making it difficult, to get a 
mathematical model describing it in the correct way. 
Several model-dependent approaches were applied to 
each dissolution profile. The use of model-dependent 
methods has been suggested primarily for the situation of 
many time points. The linearization of ACE dissolution 
Figure 3: Mean dissolution profile of the ratio of AUC
Figure 4: Mean dissolution profile of the ratio of mean dissolution time
Figure 1: Mean dissolution profile of percentage dissolved Figure 2: Mean dissolution profile of the ratio of percentage dissolved; 
[Note: The percent coefficient of variance at the earlier time points 
should not be more than 20% and at the other time points should not 
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profiles by using the equations presented in Table 5 
would characterize the differences found between all 
batches. Considering the higher determination coefficient 
(r 2 . 0.98), the preferred model that fits best to the 
dissolution data of reference was the Weibull distribution 
model. Weibull can describe the dissolution curve in terms 
of shape and scale parameter. The shape parameter b 
characterize the curve as exponential (b 5 1), S-shaped 
with upward curvature followed by turning point (b . 1) 
or parabolic, with a higher initial slope and after that 
consistent with exponential (b , 1). As dissolution 
slowed across the formulations, scale parameter became 
larger and shape factor decreased that indicate that slower 
formulation possessed lesser sigmoid shape. The lowest 
value of the ratio of rate constant of test to reference 
formulation from various model indicate slow release of 
drug from formulation. The value of b (Shape parameter) 
in Weibull . 1 reiterates that formulations have a S-shaped 
profile, but ratio of Weibull b was less than one indicating 
that test formulations have less S shape as compared to 
standard. Location parameter (time parameter) Td can 
be calculated from a and b parameters (a 5 (Td )b) and 
represents the time interval necessary to dissolve 63.2% of 
the drug present in pharmaceutical dosage form.[13] In the 
case of T3 formulation maximum (55 min) was required 
to dissolve 63.2% drug as compared to other formulation. 
As compared to reference (16.18 min), faster release was 
found in T1 formulation (14.28 min).
Among other models weibull was considered a good 
model once it passes the parameters that are sensitive 
to the change of dissolution profiles. Overall, this 
study provides experimental evidence for the successful use 
of the Weibull function in drug release studies.
CONCLUSION
The main objective of this work was to apply several profile 
comparison approaches with the intent to investigate 
several methods and to gain familiarity with the numerical 
results. It is difficult to assess the extent to which the various 
approaches described in the literature and FDA guidance 
are used to compare dissolution profile data. Each method 
used here for the comparison of dissolution profiles seems 
to be applicable and useful. It is evident from the literature 
that no single approach is widely accepted to determine 
if dissolution profiles are similar. Statistical methods 
are more discriminative and provide detailed information 
about dissolution data. Model-dependent methods 
investigate the mathematical equations that describe the 
release profile in function of some parameters related 
to the pharmaceutical dosage forms so the quantitative 
interpretation of the values is easier. These methods seem 
to be useful in the formulation-development stage. The f1 
and f2 are sensitive to the number of dissolution time points 
and the basis of the criteria for deciding the difference 
or similarity between dissolution profiles is unclear. The 
Weibull distribution model has been used for the kinetic 
analysis of release of aceclofenac formulations.
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